Y Intercept Hong Kong Ltd Sells 6,475 Shares of DaVita Inc. $DVA

Y Intercept Hong Kong Ltd lessened its holdings in shares of DaVita Inc. (NYSE:DVA) by 74.2% during the third quarter, Holdings Channel reports. The firm owned 2,250 shares of the company’s stock after selling 6,475 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in DaVita were worth $299,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hantz Financial Services Inc. increased its stake in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the period. Mid American Wealth Advisory Group Inc. bought a new stake in DaVita in the second quarter valued at $36,000. Canada Pension Plan Investment Board purchased a new position in DaVita during the 2nd quarter valued at $43,000. Ameritas Advisory Services LLC bought a new position in DaVita in the 2nd quarter worth $47,000. Finally, Employees Retirement System of Texas purchased a new stake in shares of DaVita in the 2nd quarter worth about $49,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Stock Up 5.2%

DaVita stock opened at $149.42 on Friday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $178.38. The company has a market capitalization of $10.55 billion, a P/E ratio of 15.08, a PEG ratio of 0.50 and a beta of 0.99. The stock’s 50 day moving average is $114.70 and its 200 day moving average is $125.11.

DaVita (NYSE:DVA) last released its earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. During the same period in the previous year, the company posted $2.24 earnings per share. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. As a group, equities analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on DVA. Barclays increased their price target on shares of DaVita from $143.00 to $158.00 and gave the stock an “equal weight” rating in a research note on Tuesday. TD Cowen reissued a “hold” rating on shares of DaVita in a research report on Tuesday. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. Truist Financial set a $158.00 price target on DaVita in a research note on Thursday. Finally, Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $160.50.

Trending Headlines about DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Q1 earnings beat and revenue beat drove the immediate market move; street coverage says the results and management commentary explain the gap‑up. DaVita (NYSE:DVA) Shares Gap Up After Strong Earnings
• Positive Sentiment: News summaries and market stories point to the same drivers (earnings, guidance and volume) as the reason the stock is “rocketing” higher. Why Is DaVita (DVA) Stock Rocketing Higher Today
• Positive Sentiment: Transcript coverage of the Q1 call provides detail on results and FY guidance (management set FY2026 EPS guidance), reinforcing investor confidence in cash flow and earnings trajectory. DaVita (DVA) Q1 2025 Earnings Call Transcript
• Positive Sentiment: Value-oriented outlets (Zacks) are highlighting DVA as a long‑term value idea and discussing the stock in the context of earnings-estimate strength, supporting greater retail/institutional interest. Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
• Positive Sentiment: Additional Zacks coverage frames DVA as attractive to value investors based on earnings revisions and style scores, which can drive further interest from that investor cohort. Should Value Investors Buy DaVita (DVA) Stock?
• Positive Sentiment: DVA is being featured in thematic/retirement stock lists (Buffett‑style picks), which can lift retail demand and perception of DVA as a long‑term holding. 3 Warren Buffett-Style Stocks for a Golden Retirement
• Neutral Sentiment: Industry/strategic news: an item on Elara Caring and Ares’ backing mentions DaVita in the kidney care ecosystem — relevant to strategic positioning but not an immediate earnings catalyst. Elara Caring Backed By Ares’ Private Equity Group, Kidney Care Provider DaVita
• Neutral Sentiment: Context pieces exploring DVA within the DJIA healthcare space provide useful comparative data but are informational rather than near‑term catalysts. Explore DaVita Within Dow Jones Industrial Average Healthcare Space
• Negative Sentiment: Several analysts are mixed on DVA’s outlook; divergent analyst views could cap upside if estimates or sentiment turn less favorable. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and DaVita (DVA)

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.